New peptide treatments for mitochondrial disorders
First-in-class peptide therapeutics for mitochondrial disorders: molecular mechanism of action and optimization of design
['FUNDING_R01'] · UNIVERSITY OF CONNECTICUT STORRS · NIH-10838475
This study is looking at special peptides called Szeto-Schiller (SS) peptides to see if they can help improve energy production in cells, which is important for people with conditions like Alzheimer's and other brain disorders.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CONNECTICUT STORRS (nih funded) |
| Locations | 1 site (STORRS-MANSFIELD, UNITED STATES) |
| Trial ID | NIH-10838475 on ClinicalTrials.gov |
What this research studies
This research investigates the use of Szeto-Schiller (SS) peptides to improve mitochondrial function, which is crucial for energy metabolism and overall cellular health. The team aims to understand how these peptides work at a molecular level and to optimize their design for better therapeutic effects. By employing various scientific methods, including computational modeling and cellular systems, the research seeks to uncover the mechanisms behind the peptides' effectiveness in treating conditions related to mitochondrial dysfunction, such as Alzheimer's disease and other neurodegenerative disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with mitochondrial diseases or neurodegenerative conditions like Alzheimer's disease.
Not a fit: Patients with non-mitochondrial related disorders or those who do not have neurodegenerative conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the health and quality of life for patients with mitochondrial disorders.
How similar studies have performed: Previous research has shown promising results with SS peptides in preclinical and clinical trials, indicating a potential breakthrough in treating mitochondrial dysfunction.
Where this research is happening
STORRS-MANSFIELD, UNITED STATES
- UNIVERSITY OF CONNECTICUT STORRS — STORRS-MANSFIELD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALDER, NATHAN N — UNIVERSITY OF CONNECTICUT STORRS
- Study coordinator: ALDER, NATHAN N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Animal Diseases